Valion Bio weighs sale of Velocity Bioworks after unsolicited acquisition interest
VBIO•Valion Bio is evaluating a possible sale of Velocity Bioworks after unsolicited acquisition inquiries, but discussions remain preliminary and no transaction has been agreed. A sale could provide capital for Entolimod development and other priorities while retaining production rights and manufacturing capabilities.
1. Preliminary sale review
Valion Bio is evaluating a possible sale of Velocity Bioworks after receiving unsolicited acquisition inquiries. Any transaction would prioritize retaining production rights and continued manufacturing capabilities for Entolimod, and could extend to other pipeline assets. Velocity will continue operating and pursuing new customers during the review.
